Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Antimicrobial resistance

No-deal Brexit could see UK locked out of EU infectious disease surveillance data, chief medical officer warns

Exclusive: The UK could lose access to the Surveillance Atlas of Infectious Diseases, an EU-wide surveillance scheme tracking disease outbreaks and resistance to antibiotics, if it leaves the EU without a deal in place.

Dame Sally Davies, CMO for England

Source: Charles Shearn / The Pharmaceutical Journal

Dame Sally Davies, chief medical officer for England, said that access to EU health databases “won’t be resolved until we know what form of Brexit we’re having”

A no-deal Brexit could see the UK lose access to an EU-wide online tracker of infectious diseases and antimicrobial resistance (AMR), Dame Sally Davies, the chief medical officer (CMO) for England, has told The Pharmaceutical Journal.

Asked if the UK would still be able to access — and contribute to — The European Centre for Disease Prevention and Control’s Surveillance Atlas of Infectious Diseases following a no-deal Brexit, she said that at the present time “we actually don’t know”.

Davies was speaking to The Pharmaceutical Journal at the Royal Pharmaceutical Society’s (RPS) Science and Research Summit, held at County Hall, London, on 8 February 2019, at which she spoke on the UK’s AMR strategy from 2019 and beyond.

The government had sought to retain access, Davies said, and was “working very hard to try and make sure that we can”.

“But it’s not resolved, and it won’t be resolved until we know what form of Brexit we’re having.”

The Surveillance Atlas of Infectious Diseases uses data from EU member states to provide updates on reported and confirmed cases of infectious disease, and on AMR to specific antibiotics. Under the current Brexit withdrawal agreement, the UK will “cease to be entitled to access any network, any information system and any database established on the basis of [EU] law” at the end of any transition period agreed for leaving the EU. A no-deal Brexit could see UK access lost as early as 30 March 2019, the day after Brexit is scheduled to happen.

Davies also said that pharmaceutical companies were “queuing up” to join a new pilot funding model where they would be rewarded for developing new antimicrobials, rather than paid by sales volume. The pilot, Davies said, will “look at how we value antibiotics, and pay for the value. It’s very experimental”, adding that the UK was the first country in the world to pilot market incentives for new antimicrobials.

The government announced its five-year plan for tackling AMR in January 2019, which announced the proposal for “delinking” payments to drug companies from the volume of antibiotics sold and instead “basing the payment on a [National Institute for Health and Care Excellence]-led assessment of the value of the medicines and supporting good stewardship”.

On the morning of the RPS Summit it was also announced that Davies would step down as England’s CMO in October 2019, to take up the role of Master of Trinity College, Cambridge. Reflecting on her term as CMO, Davies said that there was “much more awareness [of AMR] now. We’ve completed our first five-year plan very effectively.

“I’m really pleased with how we’ve brought all the professions together — look at the importance of pharmacists, and all the recognition the profession gets — to plan the vision for 20 years, and what we are going to do over the next five. I think it’s a really good piece of work.”

The Department for Health and Social Care did not wish to comment on Brexit arrangements.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206154

Readers' comments (1)

  • The talk at the RPS Summit on 8th February was impressive, fascinating, and reassuring in that the problem was presented as an enormous challenge, but one that humanity (including pharmacy) has the capacity to overcome.

    Just to add to the initiatives you may be aware of, ones that involve medication alternatives to antibiotics are always worth knowing about. London, Bucks and Berks pharmacists might want to know of an RPS LNW dermatology meeting on 'Benefits of using topical retinoids to treat acne'. Booking is now open. Details and Booking from LNW Events page at:
    https://www.rpharms.com/events?details=3718/Benefits%20of%20Using%20Topical%20Retinoids%20to%20Treat%20Acne
    This will focus on treatments for Acne that do not contain antibacterials and why antibiotic treatment for Acne should be limited. Venue Harrow (Kenton area), date 26th February - evening.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.